Spectacle Lenses for Myopia Management

In 2025, Essilor Stellest spectacle lenses received FDA approval for the first specialty myopia control glasses in the United States. Our office and skilled opticians are trained to customize frame selection and fitting to optimize vision and slow myopia progression in these lenses. Other brands such as Miyosmart and Myovision are pending FDA approval and not available to order in the US yet but are available in Canada. Myopia monitoring appointments are recommended for all Stellest wearers to ensure treatment effectiveness long term.

Essilor® Stellest® lenses are the first and only FDA market authorized spectacle lens to slow the progression of nearsightedness in children*1.

Why choose Essilor® Stellest® lenses for your child?

Essilor® Stellest® lenses slowed myopia progression by 71% on average over 2 years*1.

Interested in learning more?
Contact our office to schedule an appointment.

Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment.
1. Essilor International, data on file (2025).